



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 327/04, 411/04		A1	(11) International Publication Number: WO 95/29174
			(43) International Publication Date: 2 November 1995 (02.11.95)
(21) International Application Number: PCT/EP95/01503		nels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). HALLETT, Peter [GB/GB]; Glaxo Research and Development Limited, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).	
(22) International Filing Date: 21 April 1995 (21.04.95)			
(30) Priority Data: 9408091.8 23 April 1994 (23.04.94) GB 9408103.1 23 April 1994 (23.04.94) GB 9408112.2 23 April 1994 (23.04.94) GB		(74) Agents: QUILLIN, Helen, Kaye et al.; Glaxo plc, Glaxo House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).	
(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(72) Inventors; and (75) Inventors/Applicants (for US only): GOODYEAR, Michael, David [GB/GB]; Glaxo Research and Development Limited, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). DWYER, P., Owen [IE/GB]; Glaxo Research and Development Limited, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). HILL, Malcolm, Leithhead [GB/GB]; Glaxo Research and Development Limited, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). WHITEHEAD, Andrew, Jonathan [GB/GB]; Glaxo Research and Development Limited, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). HORNBLY, Roy [GB/GB]; Glaxo Research and Development Limited, Gun-		Published <i>With international search report.</i>	
(54) Title: PROCESS FOR THE DIASTEREOSELECTIVE SYNTHESIS OF NUCLEOSIDE ANALOGUES			
(57) Abstract <p>A diastereoselective process for the preparation of compounds of formula (I), wherein W is S, S=O, SO₂, or O; X is S, S=O, SO₂, or O; R₁ is hydrogen or acyl, and R₂ is a purine or pyrimidine base or an analogue or derivative thereof, is described.</p> <div style="text-align: right;"> (I) </div>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**PROCESS FOR THE DIASTEREOSELECTIVE SYNTHESIS OF
NUCLEOSIDE ANALOGUES**

5 The present invention relates to a diastereoselective process for the preparation of optically active *cis*-nucleoside analogues and derivatives.

10 Nucleosides and their analogues and derivatives are an important class of therapeutic agents. For example, a number of nucleoside analogues have shown antiviral activity against retroviruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and human T-lymphotropic virus (HTLV) (PCT publication WO 89/05662 and European Patent publication 0349242 A2).


15 In particular, 4-Amino-1-(2*R*-hydroxymethyl-[1,3]oxathiolan-5*S*-yl)-1*H*-pyrimidin-2-one, which may be represented by the following formula:



20 (also known as 3TC™ or lamivudine) and its pharmaceutically acceptable derivatives, disclosed in International application PCT/GB91/00706, publication no. WO91/17159, has been described as having antiviral activity, in particular against retroviruses such as the human immunodeficiency viruses (HIV's), the causative agents of AIDS (WO91/17159) and hepatitis B virus (HBV) (European Patent Application Publication no. 0474119).


25 Most nucleosides and nucleoside analogues and derivatives contain at least two chiral centres (shown as * in formula (A)), and exist in the form of two pairs of optical isomers (i.e., two in the *cis*-configuration and two in the *trans*-configuration). However, generally only the *cis*-isomers exhibit useful biological activity. Therefore a general stereoselective synthesis of *cis* nucleoside
30 analogues is an important goal.

2



5 Different enantiomeric forms of the same *cis*-nucleoside analogue may, however, have very different antiviral activities. M M Mansuri et al., "Preparation of The Geometric Isomers of DDC, DDA, D4C and D4T As Potential Anti-HIV Agents", Bioorg. Med. Chem. Lett., 1 (1), pp. 65-68 (1991). Therefore, a general and economically attractive stereoselective synthesis of the enantiomers of the biologically active *cis*-nucleoside analogues is an
10 important goal.

International patent application publication no. WO92/20669 discloses a diastereoselective process for producing optically active *cis*-nucleoside analogues and derivatives of formula (I).
15




wherein

W is S, S=O, SO₂, or O;

20 X is S, S=O, SO₂ or O;

R₁ is hydrogen or acyl; and

R₂ is a desired purine or pyrimidine base or an analogue or derivative thereof; the process comprising the step of reacting the desired purine or pyrimidine base or analogue thereof with an intermediate of formula (IIa) or (IIb)
25




wherein

30 R₃ is a substituted carbonyl or carbonyl derivative; and

L is a leaving group;

using a Lewis acid of the formula (III)



wherein

- 5 R_5 , R_6 and R_7 are independently selected from the group consisting of hydrogen; C_{1-20} alkyl optionally substituted by fluoro, bromo, chloro, iodo, C_{1-6} alkoxy or C_{6-20} aryloxy; C_{7-20} aralkyl optionally substituted by halogen, C_{1-20} alkyl or C_{1-20} alkoxy C_{6-20} aryl optionally substituted by fluoro, bromo, chloro, iodo, C_{1-20} alkyl or C_{1-20} alkoxy; trialkylsilyl; fluoro; bromo; chloro and iodo; and
- 10 R_8 is selected from the group consisting of fluoro; bromo; chloro; iodo; C_{1-20} sulphonate esters, optionally substituted by fluoro, bromo, chloro or iodo; C_{1-20} alkyl esters optionally substituted by fluoro, bromo, chloro or iodo, polyvalent halides; trisubstituted silyl groups of the general formula $(R_5)(R_6)(R_7)Si$ (wherein R_5 , R_6 , and R_7 are as defined above); saturated or unsaturated selenenyl C_{6-20} aryl; substituted or unsubstituted C_{6-20} arylsulphenyl; substituted or unsubstituted C_{6-20} alkoxyalkyl; and trialkylsiloxy.
- 15

20 The process of WO92/20669 allows the stereo-controlled synthesis of a racemic cis-nucleoside analogue from an equimolar mixture of (IIa) and (IIb), and of a given enantiomer of a desired cis-nucleoside analogue in high optical purity if the starting material is optically pure (IIa) or (IIb). However, the WO92/20669 process relies on the use of a Lewis acid of formula (III).


25 There are a number of disadvantages associated with the use of such Lewis acids. In particular, they are highly reactive and unstable compounds and there are therefore hazards associated with their use. Furthermore, they are expensive and have significant toxic effects. These disadvantages are of particular importance in relation to the large-scale production of nucleoside analogues in factory processes.

30

We have now found that, by judicious selection of the leaving group L in intermediates (IIa) and (IIb), the reaction with the purine or pyrimidine base, or

analogue thereof, can be successfully effected without the addition of a Lewis acid catalyst, and in particular, without the addition of a Lewis acid of formula (III).

5 The present invention accordingly provides a stereoselective process for producing cis-nucleoside analogues and derivatives of formula (I)



wherein


10 W is S, S=O, SO₂, or O;

X is S, S=O, SO₂, or O;

R₁ is hydrogen or acyl; and

R₂ is a purine or pyrimidine base or an analogue thereof;

the process comprising the step of glycosylating the purine or pyrimidine base
15 or analogue or derivative thereof with an intermediate of formula (IVa) or (IVb)




wherein R_3 is a substituted carbonyl or carbonyl derivative; and

20 G represents halo, cyano or $R^9SO_3^-$ where R^9 represents alkyl optionally substituted by one or more halo, or optionally substituted phenyl; characterised in that the glycosylation reaction is effected without the addition of a Lewis acid catalyst.

25 In a preferred embodiment, the present invention provides a stereoselective process for producing cis-nucleoside analogues and derivatives of formula (I) as previously defined, which process comprises the step of glycosylating the purine or pyrimidine base or analogue or derivative thereof with an intermediate of formula (IVa) or (IVb) as previously defined, characterised in that the glycosylation reaction is effected without the addition of a Lewis acid of formula (III):

5



wherein

5 R_5 , R_6 and R_7 are independently selected from the group consisting of hydrogen; C_{1-20} alkyl optionally substituted by fluoro, bromo, chloro, iodo, C_{1-6} alkoxy or C_{6-20} aryloxy; C_{7-20} aralkyl optionally substituted by halogen, C_{1-20} alkyl or C_{1-20} alkoxy; C_{6-20} aryl optionally substituted by fluoro, bromo, chloro, iodo, C_{1-20} alkyl or C_{1-20} alkoxy; trialkylsilyl; fluoro; bromo; chloro and iodo; and

10 R_8 is selected from the group consisting of fluoro; bromo; chloro; iodo; C_{1-20} sulphonate esters, optionally substituted by fluoro, bromo, chloro or iodo; C_{1-20} alkyl esters optionally substituted by fluoro, bromo, chloro or iodo, polyvalent halides; trisubstituted silyl groups of the general formula $(R_5)(R_6)(R_7)Si$ (wherein R_5 , R_6 , and R_7 are as defined above); saturated or unsaturated
15 selenenyl C_{6-20} aryl; substituted or unsubstituted C_{6-20} arylsulphenyl; substituted or unsubstituted C_{6-20} alkoxyalkyl; and trialkylsiloxy.

It will be appreciated that, if the glycosylation step is carried out using an equimolar mixture of intermediates (IVa) and (IVb), a racemic mixture of cis-
20 nucleoside analogues will be obtained. However, it is preferred that glycosylation is effected using an optically pure compound of formula (IVa) or (IVb), thereby producing the desired cis-nucleoside analogue in high optical purity.

25 A "nucleoside" is defined as any compound which consists of a purine or pyrimidine base linked to a pentose sugar.

As used herein, a "nucleoside analogue or derivative" is a compound containing a 1,3-oxathiolane, 1,3-dioxolane or 1,3-dithiolane linked to a purine
30 or pyrimidine base or an analogue thereof which may be modified in any of the following or combinations of the following ways: base modifications, such as addition of a substituent (e.g., 5-fluorocytosine) or replacement of one group by an isosteric group (e.g., 7-deazaadenine); sugar modifications, such as

substitution of hydroxyl groups by any substituent or alteration of the site of attachment of the sugar to the base (e.g., pyrimidine bases usually attached to the sugar at the N-1 site may be, for example, attached at the N-3 or C-6 site and purines usually attached at the N-9 site may be, for example, attached at N-7).

A purine or pyrimidine base means a purine or pyrimidine base found in naturally occurring nucleosides. An analogue thereof is a base which mimics such naturally occurring bases in that its structure (the kinds of atoms and their arrangement) is similar to the naturally occurring bases but may either possess additional or lack certain of the functional properties of the naturally occurring bases. Such analogues include those derived by replacement of a CH moiety by a nitrogen atom, (e.g., 5-azapyrimidines such as 5-azacytosine) or conversely (e.g., 7-deazapurines, such as 7-deazaadenine or 7-deazaguanine) or both (e.g., 7-deaza, 8-azapurines). By derivatives of such bases or analogues are meant those bases wherein ring substituents are either incorporated, removed, or modified by conventional substituents known in the art, e.g., halogen, hydroxyl, amino, C₁₋₆ alkyl. Such purine or pyrimidine bases, analogues and derivatives are well known to those skilled in the art.


As used herein, halo means bromo, chloro, fluoro or iodo.

As used herein, unless otherwise stated, alkyl means straight, branched or cyclic saturated hydrocarbon groups, or mixtures thereof.


Optionally substituted phenyl means unsubstituted phenyl or phenyl substituted by one or more C₁₋₆alkyl, nitro, amino, halo or cyano groups.

Preferably R₂ is a pyrimidine base. More preferably R₂ is cytosine or 5-fluorocytosine.

R₃ is a carbonyl linked to hydrogen, hydroxyl, trialkylsilyl, trialkylsiloxy, C₁₋₃₀ alkyl, C₇₋₃₀ aralkyl, C₁₋₃₀ alkoxy, C₁₋₃₀ alkylamine (secondary or tertiary), C₁₋₃₀ alkylthio; C₆₋₂₀ aryl; C₂₋₂₀ alkenyl; C₂₋₂₀ alkynyl; or R³ is 1,2-dicarbonyl, such as



- optionally substituted with C₁₋₆ alkyl or C₆₋₂₀ aryl;
 5 or R³ is an anhydride, such as



- optionally substituted with C₁₋₆ alkyl or C₆₋₂₀ aryl;
 10 or R³ is an azomethine linked at nitrogen to hydrogen, C₁₋₂₀ alkyl or C₁₋₁₀ alkoxy or C₁₋₂₀ dialkylamino and at carbon to hydrogen, C₁₋₂₀ alkyl, or C₁₋₂₀ alkoxy;
 or R³ is a thiocarbonyl (C=S) substituted with hydroxyl, C₁₋₂₀ alkoxy, or C₁₋₂₀ thiol.

- 15 Preferably R₃ represents a group -C(=O)OR₄ where R₄ represents an optionally substituted alkyl group. Preferably R₄ represents a chiral auxiliary.

- The term "chiral auxiliary" describes an asymmetric molecule that is used to
 20 effect the chemical resolution of a racemic mixture. Such chiral auxiliaries may possess one chiral centre such as α-methylbenzylamine or several chiral centres such as menthol. The purpose of the chiral auxiliary, once built into the starting material, is to allow simple separation of the resulting diastereomeric mixture. See, for example, J Jacques et al., Enantiomers, Racemates and
 25 Resolutions, pp. 251-369, John Wiley & Sons, New York (1981).

- Preferably the chiral auxiliary R₄ will be selected from (d)-menthyl, (l)-menthyl, (d)-8-phenylmenthyl, (l)-8-phenylmenthyl, (+)- norephedrine and (-)- norephedrine. More preferably R⁴ is (l)-menthyl, or (d)-menthyl, most preferably
 30 (l)-menthyl.

Preferably W is O.


Preferably X is S.

Preferably G represents halo such as Cl, Br or I, more preferably Cl,

The intermediates of formulae (IVa) and (IVb) may be isolated or they may conveniently be generated in situ.

5

Suitably the intermediates of formulae (IVa) and (IVb) are generated from the corresponding trans alcohols of formulae (Va) and (Vb):



10

wherein R_3 , W and X are as previously defined, or from the epimeric cis alcohols of formulae (Vc) and (Vd):



15

by reaction with a reagent, suitable to introduce the group G.

Suitable reagents for introducing the group G will be readily apparent to those skilled in the art and include halogenating agents such as, for example oxalyl bromide. Preferred halogenating agents are Vilsmeier-type reagents, which may conveniently be generated in situ by reaction of an N,N-disubstituted amide, such as dimethylformamide (DMF), and a halogenating agent such as an oxalyl halide, e.g. oxalyl chloride, a thionyl halide, e.g. thionyl chloride, a phosphorus halide, e.g. phosphorus trichloride or phosphorus oxychloride, an alkyl or phenyl sulphonyl halide or anhydride. The halogenation reaction is suitably effected under conventional conditions.

The intermediate of formula (IVa) or (IVb) is reacted with a silylated purine or pyrimidine base, conveniently in a suitable organic solvent such as a hydrocarbon, for example, toluene, a halogenated hydrocarbon such as dichloromethane, a nitrile, such as acetonitrile, an amide such as dimethylformamide, an ester, such as ethyl acetate, an ether such as

30

tetrahydrofuran, or a ketone such as acetone, or a mixture thereof, preferably at elevated temperature, such as the reflux temperature of the chosen solvent.

5 Silylated purine and pyrimidine bases may be prepared as described in WO92/20669, the teaching of which is incorporated herein by reference, for example by reacting the purine or pyrimidine base with a silylating agent such as t-butyldimethylsilyl triflate, 1, 1, 1, 3, 3, 3-hexamethyldisilazane, trimethylsilyl triflate or trimethylsilyl chloride, with acid or base catalyst, as appropriate. Suitable methods are described in detail in the accompanying examples.

10 The cis-nucleoside analogue obtained from the reaction of the compound of formula (I) with the purine or pyrimidine base or analogue thereof may then be reduced to give a specific stereoisomer of formula (I). Appropriate reducing agents will be readily apparent to those skilled in the art and include, for example, hydride reducing agents such as lithium aluminium hydride, lithium borohydride or sodium borohydride. We have found that stereointegrity is maintained using sodium borohydride in the presence of a phosphate or borate buffer, for example dipotassium hydrogen phosphate, as the reducing agent.

20 According to the process of the invention, as well as the process described in WO92/20669, the final compound is typically obtained as a solution in a polar solvent, such as an aqueous solvent. This presents a practical problem in that compounds of formula (I) have a high solubility in polar media, making their efficient isolation from such media difficult. We have now found that compounds of formula (I) may be efficiently isolated from solution in polar solvents by formation of a salt having poor aqueous solubility. If desired, the water-insoluble salt may subsequently be converted to the free base, or to a different salt thereof by conventional methods. We have further found that the salicylate salt is particularly suitable for this purpose.

30 The present invention thus provides a process as previously described further comprising the step of isolating the compound of formula (I) as a water-insoluble salt, especially a salicylate salt.

Salicylate salts of compounds of formula (I) are within the scope of the pharmaceutically acceptable derivatives described and claimed in European Patent Application publication no. 0382526 and publication no. WO91/17159, but are not specifically disclosed therein. Such salts are therefore novel and
5 form a further aspect of the present invention.

In a further or alternative aspect, the present invention provides salicylate salts of compounds of formula (I), or hydrates thereof.

10 In particular, we have found that formation of the salicylate salt of 4-amino-1-(2R-hydroxymethyl-[1,3]oxathiolan-5S-yl)-1H-pyrimidin-2-one (lamivudine, 3TC™) affords considerable advantages for the isolation of that compound from polar solvents.

15 In a preferred embodiment the invention therefore provides 4-amino-1-(2R-hydroxymethyl)-[1,3]oxathiolan-5S-yl)-1H-pyrimidin-2-one salicylate, or hydrates thereof.

The salicylate salt of lamivudine is a pharmaceutically acceptable salt and as
20 such it and its hydrates may be used as antiviral agents as described in WO91/17159, which is incorporated herein by reference.

The salicylate salt of lamivudine or its hydrates may be formulated as a pharmaceutical composition as described in WO91/17159.

25 The salicylate salts of compounds of formula (I) may be prepared by treating a solution containing a compound of formula (I) with salicylic acid. Suitable solvents include for example, water and polar organic solvents such as ethers, for example tetrahydrofuran or dioxan and alcohols, for example methanol and ethanol, or mixtures of solvents, in particular mixtures containing an organic
30 solvent and water.

The salicylate salts are conveniently converted, if desired, to the corresponding free bases by treatment with a base, suitably a tertiary amine such as, for
35 example triethylamine.

Other suitable water-insoluble salts and methods for their preparation and conversion to free bases will be readily appreciated by those skilled in the art.

5 Intermediate alcohols (Va) and (Vb) and the epimeric cis alcohols (Vc) and (Vd) may be prepared by the methods described in WO92/20669, for example, by reduction of the corresponding carbonyl compounds or by condensation of an aldehyde of formula R_3 -CHO, or a derivative thereof, with hydroxyacetaldehyde or mercaptoacetaldehyde, or suitable derivatives thereof. Further details of the
10 preparation of such alcohols may be found in the accompanying examples.

Compounds of formulae (Va) and (Vb) are key intermediates for the preparation of enantiomerically pure cis-nucleoside analogues or derivatives, according to the process of the invention. The absolute stereochemistry of the groups R_3 , W and X in (Va) or (Vb) is preserved in the resulting cis-nucleoside analogue or
15 derivative of formula (I).

Reactions for the preparation of alcohols of formulae (Va) and (Vb) and their cis epimers (Vc) and (Vd) typically result in the formation of mixtures of isomers.
20 When compounds of formulae (Va) or (Vb) are isolated by crystallisation from mixtures containing their enantiomers and/or their cis stereoisomers, the yield may be limited by the proportion of the desired isomer (Va) or (Vb) present in solution.

25 We have now found that crystallisation of the trans isomers (Va) and (Vb) is favoured over the crystallisation of the corresponding cis isomers (Vc) and (Vd). Where R_3 is an achiral moiety, a 1:1 mixture of the trans isomers (Va) and (Vb) may be crystallised from mixtures of the cis and trans isomers (Va), (Vb), (Vc) and (Vd).

30 Accordingly, the present invention provides, in a further or alternative aspect, a method for enhancing the yield of the trans isomers (Va) and (Vb) from a mixture of the trans and cis isomers, which method comprises treatment of the mixture of trans and cis isomers, at least partially in solution, with an agent

capable of effecting interconversion of the isomers without complete suppression of the crystallisation of the trans isomers.

5 We have further discovered that, where R_3 is a chiral moiety, a single trans enantiomer of formula (Va) or (Vb) may be selectively crystallised from a mixture of stereoisomers.

10 Thus, for example, compounds of formula (Va) wherein R_3 represents $-C(=O)R_4$, where R_4 is l-menthyl, can be selectively crystallised from a mixture of stereoisomers, in particular a mixture containing alcohols (Va), (Vb) and the epimeric cis alcohols (Vc) and (Vd).

15 Similarly, compounds of formula (Vb) wherein R_3 represents $-C(=O)R_4$, where R_4 is d-menthyl, can be selectively crystallised from a mixture of stereoisomers, in particular a mixture containing alcohols (Va), (Vb) and the epimeric cis alcohols (Vc) and (Vd).

20 Therefore, in a preferred aspect, the present invention provides a method for enhancing the yield of a single enantiomer of formula (Va) or (Vb) from a mixture of isomers, which method comprises treatment of the mixture of isomers, at least partially in solution, with an agent capable of effecting interconversion of the isomers without complete suppression of the crystallisation of the desired single enantiomer (Va) or (Vb).

25 Agents capable of effecting interconversion of the isomers without complete suppression of the crystallisation of the trans isomers include, for example, alcohols, such as, for example, methanol, ethanol, n-propanol, i-propanol, n-butanol, i-butanol, t-butanol, and organic bases, in particular tertiary amines, for example, pyridine and triethylamine and Hunig's base. A preferred agent is
30 triethylamine.

The interconversion of isomers may be effected in any suitable solvent or mixture of solvents which does not otherwise react with the alcohols of formulae (Va) or (Vb) or their cis isomers, under conditions of concentration and
35 temperature which permit crystallisation of the desired isomer or isomers and

which do not cause significant degradation of the desired isomer or isomers. Suitable solvents may include for example, aliphatic or aromatic hydrocarbons, ethers, esters and chlorinated hydrocarbons. The interconversion will preferably be effected at a temperature of about -20° to 120°C, more preferably in the range of about -10° to 80°C, such as about 0° to 50°C.

It will be appreciated by those skilled in the art that selection of solvent, temperature, interconversion agent and, particularly, the quantity of the interconversion agent is best conducted as an integrated exercise dependent on the nature of the groups R₃, X and W present in the isomers. However, when an organic base is used as the interconversion agent, the preferred quantity is generally less than two mole-equivalents based on the total of all isomers of (Va) and (Vb) present.


Further guidance as to preferred reaction conditions may be gained from the accompanying examples.

The interconversion of isomers may be conducted separately from the preparation of the isomeric mixture; however, it is conveniently conducted concomitantly with that preparation.

The interconversion procedure may also be used to increase the isomeric purity of isolated (Va) or (Vb).

By means of the interconversion process, the isolated yield of the desired isomer (Va) or (Vb) may be enhanced to greater than 50% of theory (based on formation of all stereoisomers), typically to between about 60% and about 90% of theory; but it is not ruled out that yields approaching 100% of theory may be obtained.

A particularly preferred embodiment of the process of the present invention using l-menthol as chiral auxiliary is represented in Scheme 1 and is described in detail in the accompanying examples, which are to be construed as illustrative of the invention and not as limiting thereof.

Scheme 1

5

The invention is further illustrated by the following non-limiting examples. All temperatures are in degrees centigrade. DMSO means dimethyl sulphoxide.

10

Example 1**4-Amino-1-(2R-hydroxymethyl-[1,3]oxathiolan-5S-yl)-1H-pyrimidin-2-one**

(a) (2R,5R)-5-Hydroxy-[1,3]oxathiolane-2-carboxylic acid, 2S-isopropyl-5R-methyl-1R-cyclohexyl ester

A mixture of l-menthyl glyoxylate hydrate (25g) and acetic acid (2.5mL) in toluene (125mL) was stirred and heated to reflux. Water was removed by azeotropic distillation via a Dean-Stark trap. The resulting solution of l-menthyl glyoxylate was concentrated by distillation under reduced pressure collecting ca 70mL distillate, and then cooled to 20-25°. The volume was adjusted to 75mL by adding ca 15mL toluene, dithianediol (8.25g) was added, and the mixture heated at reflux for about 1h. The mixture was cooled to about 80°, and clarified. The filtrate was cooled to 0-5°, and a solution of triethylamine (1.5mL) in hexane (150mL) was added over ca 1.25h at 0-5°. The resulting suspension was stirred at 0-5° for about 6h, then the product isolated by filtration. The product was washed with a mixture of toluene and hexane (1:3, 2x50mL), and dried *in vacuo* at 40-45° to constant weight.

15 (b) (2R,5R)-5-(4-Amino-2-oxo-2H-pyrimidin-1-yl)- [1,3]oxathiolane-2-carboxylic acid, 2S-isopropyl-5R-methyl-1R-cyclohexyl ester

A solution of (2R,5S)-5-chloro-[1,3]oxathiolane-2-carboxylic acid, 2S-isopropyl-5R-methyl-1R-cyclohexyl ester was prepared as follows:

20 A solution of (2R,5R)-5-hydroxy-[1,3]oxathiolane-2-carboxylic acid, 2S-isopropyl-5R-methyl-1R-cyclohexyl ester (300g) in dichloromethane (3000mL) containing methanesulphonic acid (0.7mL) was treated with dimethylformamide (85mL), cooled to ca 8° and thionyl chloride (80mL) added over ca 10min. The resultant solution was stirred at 10-15° for ca 1.5h, then concentrated by distillation under atmospheric pressure (over ca 1.5h), collecting ca 2.1L distillate. The solution was cooled to 20-25°.

A solution of silylcytosine was prepared as follows:

30 A suspension of cytosine (115.5g), methanesulphonic acid (0.7mL) and hexamethyldisilazane (242mL) was heated in toluene (290mL) at reflux until a clear solution was obtained (ca 1.5h).

The solution of silylcytosine was treated with triethylamine (145mL), the solution of (2R,5S)-5-chloro-[1,3]oxathiolane-2-carboxylic acid, 2S-isopropyl-5R-methyl-1R-cyclohexyl ester added maintaining a gentle reflux, washing in with dichloromethane (300mL). The resulting mixture was heated at reflux for 4h, and added to a mixture of triethylamine (73mL) and water (1200mL) held at 30-35°, over ca 1.5h. The resulting suspension was stirred for ca 45min, then hexane (1200mL) added over ca 10min at 30-35°. The suspension was stirred at ambient temperature overnight, then filtered. The solid was washed with water (2x600mL) and isopropyl acetate (2x600mL), and dried *in vacuo* at 40-45° to constant weight. ¹HNMR (D₆-DMSO) δ_H 0.75 (3H,d); 0.89(d), 0.9(m), 0.91(d), 1.0-1.2(m) (9H); (9H,m); 1.43, 1.50 (2H,m); 1.67 (2H,m); 1.9-2.0 (2H,m); 3.14 (1H,dd); 3.55 (1H,dd); 4.69 (1H,dt); 5.70 (1H,s); 5.80 (1H,d), 6.36 (1H,dd), 7.28 (brs), 7.33 (brs) (2H); 7.97 (1H,d)

15 (c) 4-Amino-1-(2R-hydroxymethyl-[1,3]oxathiolan-5S-yl)-1H-pyrimidin-2-one monosalicylate

A solution of dipotassium hydrogen phosphate (137g) in water (150mL) was stirred at ca 20°, and (2R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-[1,3]oxathiolane-2-carboxylic acid, 2S-isopropyl-5R-methyl-1R-cyclohexyl ester (100g) added. IMS (750mL) was added, and the suspension stirred for 10min. A solution of sodium borohydride (20g) in water (200mL) containing sodium hydroxide solution, 25% w/w (2mL) was added over 70min, keeping the temperature in the range 15-30°. The addition funnel was rinsed with water (50mL), and the mixture stirred at 15-30° until the reaction was judged complete by HPLC (150min). The mixture was allowed to settle, and the lower aqueous layer discarded. The pH of the organic phase remaining was adjusted to 4-4.5 with conc. hydrochloric acid (27mL), whilst maintaining the temperature in the range 20-25°. The addition funnel was rinsed with water (20mL), then the pH of the solution adjusted to 6.8-7.2 with 2M sodium hydroxide solution (110mL). The addition funnel was rinsed with water (20mL), and the reaction mixture was transferred to a distillation vessel, washed in with water (50mL), and the solution heated to reflux. The solution was concentrated to ca 6.45vol under atmospheric pressure, then cooled to 20-25°.


Menthol was removed by extraction with toluene (500mL, 2 x 200mL), the aqueous phase was diluted with water (255mL) then treated with salicylic acid (36g), washing in with water (40mL). The mixture was heated to give a solution (at 71°), then cooled to 58°. The solution was seeded with authentic lamivudine salicylate, then cooled to 5-10° over ca 4h. The suspension was stirred for 1h at this temperature, then filtered. The product was washed with water (1 x 100mL, 2 x 200mL), and dried *in vacuo* at 45-50° to constant weight. ¹HNMR (D₆-DMSO) δ_H 3.11 (dd), 3.45 (dd) (2H); 3.77 (2H,m); 5.20 (1H,m); 5.82 (1H,d); 6.22 (1H,m); 6.91 (2H,m); 7.48 (1H,m); 7.62 (2H,br); 7.80 (1H,dd); 7.92 (1H,d).

(d) 4-Amino-1-(2R-hydroxymethyl-[1,3]oxathiolan-5S-yl)-1H-pyrimidin-2-one

4-Amino-1-(2R-hydroxymethyl-[1,3]oxathiolan-5S-yl)-1H-pyrimidin-2-one monosalicylate (66.7g) was stirred with IMS (470mL), and heated to 70-75° to give a solution. The solution was clarified into a crystallisation vessel, and rinsed in with a further 170mL IMS. Triethylamine (26mL) was added, and the solution distilled until 280mL remained. The solution was cooled to 70° over 20 min, seeded, then isopropyl acetate held at 60° (600mL) added over 2:25h, maintaining the temperature above 55°. The mixture was cooled to room temperature overnight, then cooled to 8-10° and stirred for 1h. The product was isolated by filtration (transferred to the filter with 30mL isopropyl acetate), washed with isopropyl acetate (2 x 130) and dried *in vacuo* at 40-45°, to constant weight. ¹HNMR (D₆-DMSO) δ_H 3.10 (1H,dd); 3.39 (1H,dd); 3.72 (2H,m); 5.15 (1H,t); 5.29 (1H,t); 5.72 (1H,d); 6.19 (1H,dd); 7.17 (1H, brs); 7.22 (1H,brs); 7.80 (1H,d).

CLAIMS

1. A stereoselective process for producing compounds of formula (I)




wherein

W is S, S=O, SO₂, or O;

X is S, S=O, SO₂, or O;

R₁ is hydrogen or acyl; and


R₂ is a purine or pyrimidine base or an analogue or derivative thereof;
the process comprising the step of reacting the purine or pyrimidine base or analogue thereof with an intermediate of formula (IVa) or (IVb)



wherein R₃ is a substituted carbonyl or carbonyl derivative; and
G represents halo, cyano or R⁵SO₂- where R⁵ represents alkyl optionally substituted by one or more halo, or optionally substituted phenyl;
characterised in that the reaction with the purine or pyrimidine base or analogue thereof is effected without the addition of a Lewis acid catalyst.

2. A process as claimed in claim 1 further comprising the step of reducing R₃ to the group R₁OCH₂.
3. A process as claimed in claim 2 wherein the reduction is effected using sodium borohydride in the presence of a borate or phosphate buffer.
4. A process as claimed in any one of claims 1 to 3 wherein R₂ is a pyrimidine base.
5. A process as claimed in claim 4 wherein R₂ is cytosine or 5-fluorocytosine.

6. A process as claimed in any one of claims 1 to 5 wherein R_3 represents a group $-C(=O)OR_4$ where R_4 represents an optionally substituted alkyl group.
7. A process as claimed in claim 6 wherein R_4 represents a chiral auxiliary.
8. A process as claimed in claim 7 wherein R_4 is selected from (d)-menthyl, (l)-menthyl, (d)-8-phenylmenthyl, (l)-8-phenylmenthyl, (+)-norephedrine and (-)-norephedrine.
9. A process as claimed in any one of claims 1 to 8 wherein W is O and X is S.
10. A process as claimed in any one of claims 1 to 9 wherein G represents Cl, Br or I.
11. A process as claimed in any one of claims 1 to 10 wherein the compound of formula (I) is isolated as a water-insoluble salt.
12. A process as claimed in any one of claims 1 to 11 wherein the compound of formula (I) is 4-amino-1-(2R-hydroxymethyl-[1,3]oxathiolan-5S-yl)-1H-pyridin-2-one or a salicylate salt thereof.
13. A process as claimed in any one of claims 1 to 12 wherein the intermediates of formulae (IVa) and (IVb) are generated from the corresponding trans alcohols of formulae (Va) and (Vb)



wherein R_3 , W and X are as defined in claim 1, or from the epimeric cis alcohols, by reaction with a reagent, suitable to introduce the group G.

14. A process as claimed in claim 13 wherein the intermediates of formulae (IVa) and (IVb) are generated in situ.
- 5 15. A method for enhancing the yield of the trans isomers (Va) and (Vb) from a mixture of the trans and cis isomers, which method comprises treatment of the mixture of trans and cis isomers, at least partially in solution, with an agent capable of effecting interconversion of the isomers without complete suppression of the crystallisation of the trans isomers.
- 10 16. A method for enhancing the yield of a single enantiomer of formula (Va) or (Vb) from a mixture of isomers, which method comprises treatment of the mixture of isomers, at least partially in solution, with an agent capable of effecting interconversion of the isomers without complete suppression of the crystallisation of the desired single enantiomer (Va) or (Vb).
- 15 17. A method as claimed in claim 16 for the selective crystallisation of compounds of formula (Va) wherein R_3 represents $-C(=O)OR_4$, where R_4 is l-menthyl from a mixture of stereoisomers containing alcohols (Va), (Vb) and the epimeric cis alcohols.
- 20 18. A method as claimed in claim 16 for the selective crystallisation of compounds of formula (Vb) wherein R_3 represents $-C(=O)OR_4$, where R_4 is d-menthyl from a mixture of stereoisomers containing alcohols (Va), (Vb) and the epimeric cis alcohols.
- 25 19. A method as claimed in claim 17 for the selective crystallisation of (2R,5R)-5-hydroxy-[1,3]oxathiolane-2-carboxylic acid, 2S-isopropyl-5R-methyl-1R-cyclohexyl ester.
- 30 20. A method as claimed in claim 19 wherein the agent capable of effecting interconversion of the isomers without complete suppression of the crystallisation of the desired single enantiomer is triethylamine.
- 35 21. A salicylate salt of a compound of formula (I), or a hydrate thereof.

22. 4-Amino-1-(2R-hydroxymethyl-[1,3]oxathiolan-5S-yl)-1H-pyrimidin-2-one
salicylate and hydrates thereof.
- 5 23. A process essentially as described in Scheme 1.
24. A process essentially as herein described with reference to Example 1.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 95/01503

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D327/04 C07D411/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 515 157 (BIOCHEM PHARMA) 25 November 1992 cited in the application see the whole document ---	1-14
A	WO,A,91 17159 (IAF BIOCHEM) 14 November 1991 cited in the application see page 9 - page 15 ---	1-14
P,A	WO,A,94 14802 (BIOCHEM) 7 July 1994 see claims; examples 10-21 -----	1-14

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

11 August 1995

Date of mailing of the international search report

18. 08. 95

Name and mailing address of the ISA
European Patent Office, P.O. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Francois, J

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 95/01503

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0515157	25-11-92	AU-B- 655973	19-01-95
		AU-A- 1639492	26-11-92
		AU-A- 1639592	26-11-92
		AU-A- 1690892	30-12-92
		AU-A- 1691392	30-12-92
		BG-A- 98310	03-01-95
		BG-A- 98311	15-08-94
		WO-A- 9220696	26-11-92
		WO-A- 9220669	26-11-92
		CN-A- 1067654	06-01-93
		CN-A- 1067245	23-12-92
		CZ-A- 9302492	16-03-94
		CZ-A- 9302493	13-04-94
		EP-A- 0515156	25-11-92
		HU-A- 67726	28-04-95
		HU-A- 67471	28-04-95
		JP-A- 5186465	27-07-93
		JP-A- 5186463	27-07-93
		NZ-A- 242817	28-03-95
		NZ-A- 242818	27-04-94
WO-A-9117159	14-11-91	AU-B- 651345	21-07-94
		AU-A- 7771991	27-11-91
		CN-A- 1058214	29-01-92
		EP-A- 0625150	23-11-94
		HU-A- 64335	28-12-93
		JP-T- 5501117	04-03-93
		NZ-A- 238017	27-06-94
		OA-A- 9559	31-01-93
WO-A-9414802	07-07-94	NONE	